ondansetron has been researched along with Auricular Fibrillation in 3 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To provide further evidence of cardiovascular adverse effects of ondansetron, including new-onset atrial fibrillation, ST segment elevation, and chest pain subsequent to ondansetron administration, and to review cardiovascular adverse events related to several 5-hydroxytryptamine type 3 (5-HT(3)) receptor antagonists." | 7.75 | Coronary vasospasm and atrial fibrillation associated with ondansetron therapy. ( Havrilla, PL; Kane-Gill, SL; Reis, SE; Seybert, AL; Verrico, MM, 2009) |
| " She received 4 mg of ondansetron intravenously for postoperative nausea and vomiting prophylaxis at the end of the procedure and an additional 4 mg in the recovery room for nausea." | 7.72 | Atrial fibrillation after ondansetron for the prevention and treatment of postoperative nausea and vomiting: a case report. ( Kasinath, NS; Malak, O; Tetzlaff, J, 2003) |
| "To provide further evidence of cardiovascular adverse effects of ondansetron, including new-onset atrial fibrillation, ST segment elevation, and chest pain subsequent to ondansetron administration, and to review cardiovascular adverse events related to several 5-hydroxytryptamine type 3 (5-HT(3)) receptor antagonists." | 3.75 | Coronary vasospasm and atrial fibrillation associated with ondansetron therapy. ( Havrilla, PL; Kane-Gill, SL; Reis, SE; Seybert, AL; Verrico, MM, 2009) |
| " She received 4 mg of ondansetron intravenously for postoperative nausea and vomiting prophylaxis at the end of the procedure and an additional 4 mg in the recovery room for nausea." | 3.72 | Atrial fibrillation after ondansetron for the prevention and treatment of postoperative nausea and vomiting: a case report. ( Kasinath, NS; Malak, O; Tetzlaff, J, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Havrilla, PL | 1 |
| Kane-Gill, SL | 1 |
| Verrico, MM | 1 |
| Seybert, AL | 1 |
| Reis, SE | 1 |
| Miller, DR | 1 |
| Kasinath, NS | 1 |
| Malak, O | 1 |
| Tetzlaff, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Efficacy and Safety of Ramosetron in Patients Undergoing Off Pump Coronary Artery Bypass Surgery[NCT02139241] | 114 participants (Actual) | Interventional | 2013-06-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 other studies available for ondansetron and Auricular Fibrillation
| Article | Year |
|---|---|
Coronary vasospasm and atrial fibrillation associated with ondansetron therapy.
Topics: Antiemetics; Atrial Fibrillation; Coronary Vasospasm; Humans; Injections, Intravenous; Male; Middle | 2009 |
Arrhythmogenic potential of antiemetics: perspectives on risk-benefits.
Topics: Antiemetics; Arrhythmias, Cardiac; Atrial Fibrillation; Droperidol; Electrocardiography; Humans; Ind | 2003 |
Atrial fibrillation after ondansetron for the prevention and treatment of postoperative nausea and vomiting: a case report.
Topics: Antiemetics; Atrial Fibrillation; Female; Humans; Middle Aged; Ondansetron; Postoperative Nausea and | 2003 |